1 ADHD and AAP Drug Safety Standards for Medicaid Children Health and Recovery Services Administration (HRSA) Dr. Jeffrey Thompson, Medical Director Fee-for-Service.

Slides:

Advertisements

Similar presentations

Update on Recent Health Reform Activities in Minnesota.

Advertisements

Implementing NICE guidance

Management of Drug Formulary Dimitry Gotlinsky Western University Managed Care Clerkship ProPharma Pharmaceutical Consultants, Inc. 06/16/06.

WHO Europe Initiative on Health of Children and Young People with Intellectual Disabilities and their Families Dr Roger Banks Consultant in the Psychiatry.

Evidence-Based Medicaid: Health Care That Works Pay for Performance: Health Care That Adds Value Jeff Thompson MD MPH Chief Medical Officer Washington.

September 10,  The ACA expands access to health insurance through improvements in Medicaid, the establishment of Affordable Insurance Exchanges,

THE INAPPROPRIATE SALE OF MEDICATION FOR PEDIATRIC USE IN SIEM REAP PROVINCE, KINGDOM OF CAMBODIA AUTHORS: Sothearith Tiv Ph., Rathi Guhadasan MBBS MRCP.

DUR Board Meeting March 12, 2008 West Virginia Department of Health and Human Resources Bureau for Medical Services Drug Utilization Review Board.

Arkansas Children’s Behavioral Health Care Commission AR DHS Division of Medical Services Pharmacy Program Laurence H. Miller, M.D., Senior Psychiatrist.

Outcomes Tool Selection Committee Kick-Off Meeting April 29, 2015.

Understanding decision making - Investigating complaints Tony Kofkin Director of Investigations Health Care Complaints Commission Dr Walid Jammal Medical.

Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence Implementing NICE guidance February 2011 NICE clinical.

Accelerating Utilization of CE Findings in Medicaid Mental Health: The Medicaid Mental Health Network for Evidence Based Care Stephen Crystal, Ph.D. Center.

HOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET Kathy Wonderly RN, BSPA, CPHQ Performance Improvement Coordinator Developed: February,

The Evidence Base for Psychosocial and Psychopharmacological Interventions for Children with Attention-Deficit/Hyperactivity Disorder, Major Depressive.

Washington’s Prescription Drug Program U sing systematic reviews to make policy decisions in the effort to contain prescription drug expenditures Siri.

Report to Los Angeles County Executive Office And Los Angeles County Health Services Agencies Summary of Key Questions for Stakeholders February 25, 2015.

1 Evidence and the next stage of health care reform: Why consumer engagement is so important Steven D. Pearson, MD, MSc President, Institute for Clinical.

Implementing NICE guidance

1 The Case Management Approach October 11, 2012 International Centre, Mississauga, ON Suzanne Lepage Private Health Plan Strategist.

Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.

Prior Authorization Criteria for PDL Classes: Alzheimer’s Anti-emetics High Potency Statins Hormone Replacement Therapy Multiple Sclerosis – Tysabri Charles.

1 Mental Health and Substance Abuse Services Division Association of Substance Abuse Providers Mike Maples October 5, 2011.

1 Beyond coverage decisions: Private health plans in the US and comparative effectiveness research Steven D. Pearson, MD, MSc, FRCP President, Institute.

A Big Unknown : How to Use Data to Improve Policy and Quality Jeffery Thompson, M.D. Chief Medical Officer Washington State Medicaid Academy Health Washington.

Clinical Management for Behavioral Health Services (CMBHS)

QSEN Primer Or, “QSEN in a Nutshell” 1.  1999—Institute of Medicine published “To Err is Human”  Determined errors have an effect on both patient satisfaction.

Linda Y. Radke, Pharm.D., BCPS, FASHP Salina Regional Health Center

Washington State Rethinking Care Project July 22, 2008.

Florida Agency for Health Care Administration Florida Center for Health Information and Policy Analysis Florida Public Health Association - Medical Director’s.

PARTNERSHIP TO IMPROVE DEMENTIA CARE THE OHIO APPROACH.

Evidence-Based Public Health Nancy Allee, MLS, MPH University of Michigan November 6, 2004.

1 Governor’s Office of Health Policy and Finance MaineCare Pharmacy Initiatives.

SPSP Medicines Paediatric Networking Event Prepared by: David Maxwell.

1 Anti-psychotic Medication in Children, Adolescents and Foster Care: Too Many, too Much, and too Young Medicaid Medical Directors Learning Network (MMDLN)

Antipsychotic Utilization: Oregon State Medicaid Ann M. Hamer, PharmD BCPP This presentation was made possible by a grant from the State Attorney General.

Arkansas Medicaid Antipsychotic Utilization in Children Arkansas Children’s Behavioral Health Care Commission AR DHS Division of Medical Services Pharmacy.

Innovations and Challenges in Coordinated Care for Chronically ill Children John M. Neff, M.D. Professor of Pediatrics University of Washington School.

Medicaid Managed Care Program for the Elderly and Persons with Disabilities Pamela Coleman Texas Health and Human Services Commission January 2003.

Disease Prevention and Health Promotion/Screening Guidelines

Locating the Best Evidence at the MUSM Libraries Mercer Medical Library Macon Health Sciences Library Memorial University.

Status Report on Development of a Medicaid Preferred Drug List Program Presentation to: The Medicaid Pharmacy & Therapeutics Committee Cynthia B. Jones.

NDTMS – Core Dataset ‘F’ NDTMS Adult Drug & Alcohol Services Core Dataset ‘F’ February 2009 Jill Smith NEPHO – NDTMS Team.

SUBSTANCE ABUSE Healthy Kansans 2010 Steering Committee Meeting May 12, 2005.

Medicaid Fee-for-Service: Prior Authorization Criteria & the Role of the DUR Board Charles Agte, Pharmacy Administrator Health Care Services June 19, 2013.

Care Packages in Substance Misuse Treatment Development of MH Care Clusters: overview  Service users in MH, clinicians found: idiosyncratic referral pathways.

Why CCOs Matter to School Nurses …….and how to become involved.

TOWARDS RECOVERY CLINICS Patient Care. Community Fit. An Integrated Approach to Comprehensive Treatment.

Nursing Process: The Foundation for Safe and Effective Care Chapter 5.

Use of Antipsychotic Drugs in Dementia Josepha A. Cheong, MD University of Florida Departments of Psychiatry and Neurology Chief, Division of Geriatric.

Background Objectives Results Methods Within State Geographic Variation in Antipsychotic Medication Treatment for Medicaid-insured Children and Adolescents.

Addressing Racial/Ethnic Differences in ADHD Diagnosis and Treatment Among Medicaid-insured Youth in California Dinci Pennap, MPH, 1 Mehmet Burcu, MS,

Early Intervention Program & Early Family Support Services: Analyzing Program Outcomes with the Omaha System of Documentation Presented to: Minnesota Omaha.

MTM WORK, Inc. The Medication Therapy Management well done at the right price 12/9/2015EXPO-34 Unit 4 - Olivier Wamain.

Practice Key Driver Diagram. Chapter Quality Network ADHD Project Jeff Epstein PhD CQN ADHD National Expert/CQN Data Analyst The mehealth Portal and CQN.

Clinical Governance – Pursuing Quality, Safety and Excellence ISBAR In Our Communication Introduction –Who, what and where you are and why are you calling.

DRUG USE PROFILES IN AN NGO-MANAGED HEALTH CENTRE VERSUS PRIVATE HEALTH PRACTITIONERS Mandal SC: Indian Pharmaceutical Association, Bengal Branch, Kolkata;

Health Care Reform IT’S COMPLEX! Jeffery Thompson, MD MPH Chief Medical Officer Washington State Medicaid.

Developing role of community pharmacy in responding to the needs of people with drug problems Karen Melville Principal Pharmacist TSMS NHS Tayside.

DHS Health Care Services Study: Potential Coverage Strategies for the Non-Disabled Population Michael Bailit Bailit Health Purchasing, LLC March 18, 2004.

Delaware's children in foster care – health service utilization May 4, 2016 Presented by: Catherine Zorc, MD, MPH, Nemours Katie Gifford, MS, Center for.

Drug Utilization Review & Drug Utilization Evaluation: An Overview

Patient Focused Drug Development An FDA Perspective

Designing Effective Accommodation Plans in Clinical Placement & Internship Settings

Public Substance Use Disorder Treatment for Youth in California County Behavioral Health Directors Association of California – All Members Meeting October.

National Medicare Prescription Drug Congress

349 (36.1%) of 966 children were prescribed ADHD medications.

The only solution that provides complete, 360° support

Primum non nocere Olabisi Oshikanlu M.D., F.A.A.P

Drug Utilization Review & Drug Utilization Evaluation: An Overview

Presentation transcript:

1 ADHD and AAP Drug Safety Standards for Medicaid Children Health and Recovery Services Administration (HRSA) Dr. Jeffrey Thompson, Medical Director Fee-for-Service (FFS) Pharmacy Program

2 Background  Evidence-based medicine WAC defines how to grade and apply evidence to make coverage decisions.  ADHD and AAP drug reviews were performed by evidence- based practice centers OHSU, RAND, and CADIE.  The Mental Health Community experts join with HRSA in examining the studies and recommending ADHD and AAP safety edits for Fee-for-Service (FFS) Medicaid Children.  The Mental Health Drugs Work Group (MHDW) reviews evidence and examines current utilization practices within the Children’s Medicaid FFS population.  The MHDW partners with community experts and HRSA to assess evidence and utilization for appropriate use of ADHD and AAP drugs for children.

3 Some key Questions When Making Coverage and Safety Decisions What is the quality of the research justifying the request? What is the estimation of harm if the treatment was to occur? What is the equally effective lower cost alternative? Is there a vulnerable population that perhaps requires higher levels of evidence?  or IRB approval/informed consent?

4 Community ADHD Drug Prescribing Practices for Medicaid FFS Children Age 17 and under FY2005

5 Community AAP Drug Prescribing Practices for Medicaid FFS Children < 3 yrs.#Clients# ABOVE RECOMMENDED DOSE Total11 ABILIFY CLOZAPINE GEODON RISPERDAL11 SEROQUEL ZPREXA 3–5 Yrs.# clients# ABOVE RECOMMENDED DOSE Total12940 ABILIFY12 CLOZAPINE-0- GEODON22 RISPERDAL9911 SEROQUEL11 ZPREXA54

6 Community AAP Drug Prescribing Practices for Medicaid FFS Children YRS#clients# ABOVE RECOMMENDED DOSE Total ABILIFY52157 CLOZAPINE-0- GEODON7925 RISPERDAL SEROQUEL ZPREXA YRS# clients# ABOVE RECOMMENDED DOSE Total ABILIFY73415 CLOZAPINE4-0- GEODON2149 RISPERDAL SEROQUEL82643 ZPREXA2468

7 Mental Health Drug Work Group Agrees on Safety Edits for ADHD and AAP  For endorsing and non-endorsing providers 1. Age limits 2. Dose limits 3. Combination limits 4. Sedatives 5. Second Opinion opportunities  For non-endorsing providers 1. Tried and failed two preferred, or 2. Some documentation of intolerance to starting with a preferred drug

8 Children’s ADHD Safety Edits ADHD MedicationsMaximum Dose Client Numbers % of Total User Population Methylphenidates >5 Years of Age> 120 mg % 3-5 Years of Age> 30 mg4152.6% < 3 Years of AgeN/A47<1% Amphetamine >5 Years of Age> 60 mg1131% 3-5 Years of Age> l5 mg3302% < 3 Years of AgeN/A30<1%

9 Mental Health Drug Work Group Safety Recommendation for APP

10 Outcomes What are the Objectives  Improve Mental Health Therapy  Define Mental Health Therapies  Measure Mental Health Therapy by Reviewing: Number of Rx’s Assessments Cognitive behavior Poly-pharmacy Poly-prescriber’s Adherence Coordination of care

11 Questions